Fresenius Kabi announced it has launched Bivalirudin for Injection, the generic version of The Medicines Company‘s Angiomax.

Bivalirudin for Injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients: 

  • With unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
  • Undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as in the REPLACE-2 study.
  • With, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), undergoing PCI – intended for use with aspirin.

Related Articles

Bivalirudin works by directly inhibiting thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. It inhibits both soluble (free) and clot-bound thrombin, is not neutralized by products of the platelet release reaction, and prolongs the activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) of normal human plasma in a concentration-dependent manner.

Bivalirudin for Injection is available as a 250mg per vial strength in single-dose vials.

For more information call (888) 386-1300 or visit